Iodandine (Tablets) Instructions for Use

ATC Code

H03CA (Iodine preparations)

Active Substance

Potassium iodide (Ph.Eur. European Pharmacopoeia)

Clinical-Pharmacological Group

Iodine preparation for the prevention and treatment of thyroid diseases

Pharmacotherapeutic Group

Thyroxine synthesis regulator – iodine preparation

Pharmacological Action

An agent containing inorganic iodine. When iodides enter the cells of the follicular epithelium of the thyroid gland, under the influence of the enzyme iodide peroxidase, iodine is oxidized to form elemental iodine, which is incorporated into the tyrosine molecule. In this case, one part of the tyrosine radicals in thyroglobulin is iodinated. Iodinated tyrosine radicals condense into thyronines, the main ones being thyroxine (T₄) and triiodothyronine (T₃). The resulting complex of thyronine and thyroglobulin is released, as a stored form of thyroid hormone, into the follicular colloid and remains in this state for several days or weeks. In case of iodine deficiency, this process is disrupted.

Potassium iodide, compensating for iodine deficiency, helps restore impaired synthesis of thyroid hormones.

With a normal iodine content in the environment, under the influence of excess iodides, the biosynthesis of thyroid hormones is inhibited, their release from thyroglobulin is reduced, the sensitivity of the thyroid gland to the pituitary thyrotropic hormone is decreased, and its secretion by the pituitary gland is blocked.

Pharmacokinetics

When taken orally, it is rapidly absorbed from the gastrointestinal tract. It is widely distributed in all tissues and body fluids.

Indications

Prevention and treatment of endemic goiter. Prevention of goiter recurrence during complex treatment with thyroid hormone preparations.

ICD codes

Dosage Regimen

Determine the dosage individually based on the patient’s age and clinical indication.

For endemic goiter prevention in children, administer a daily dose of 50-100 mcg of iodine.

For endemic goiter prevention in adolescents and adults, administer a daily dose of 100-200 mcg of iodine.

For endemic goiter treatment, use higher doses as clinically directed; the duration of therapy is determined by the physician.

To prevent goiter recurrence after complex treatment, administer a daily dose of 100-200 mcg of iodine.

Take tablets orally, after a meal, with a sufficient amount of liquid.

For long-term use, ensure regular medical supervision to monitor thyroid function.

Avoid exceeding the recommended daily dose unless specifically prescribed.

In elderly patients, use with caution and initiate therapy at the lower end of the dosing range.

Adverse Reactions

Manifestations of iodism: swelling of the nasal mucosa, urticaria, angioedema, eosinophilia, shock, tachycardia, irritability, sleep disorders, increased sweating, diarrhea (in patients over 40 years of age); in some cases, when used in doses exceeding 300-1000 mcg/day, the development of hyperthyroidism is possible (especially in elderly patients, in the presence of nodular or diffuse toxic goiter); during high-dose therapy (more than 1 mg/day), iodine-induced goiter and, accordingly, hypothyroidism may develop.

Contraindications

Hypersensitivity to iodine preparations; pronounced hyperthyroidism, latent hyperthyroidism (when used in doses exceeding 150 mcg/day), toxic adenoma, nodular or diffuse toxic goiter (when used in doses of 300-1000 mcg/day), dermatitis herpetiformis (Duhring’s disease), pregnancy and breastfeeding (when used in doses of 1-2 mg/day).

Use in Pregnancy and Lactation

During pregnancy, use is possible only in recommended doses, because iodine penetrates the placental barrier and can cause the development of hypothyroidism and goiter in the fetus.

Iodine is excreted in breast milk. When used by the mother during lactation (breastfeeding) in doses of more than 1 mg/day, there is a risk of developing hypothyroidism in the infant.

Use in Renal Impairment

During therapy in patients with renal insufficiency, hyperkalemia may develop.

Pediatric Use

Can be used in children according to indications in age-appropriate recommended doses and dosage forms.

Geriatric Use

Should be used with caution in elderly patients due to the risk of developing hyperthyroidism in this category of patients.

Special Precautions

During therapy in patients with renal insufficiency, hyperkalemia may develop.

Drug Interactions

With simultaneous high-dose therapy with iodine and potassium-sparing diuretics, hyperkalemia may develop; with lithium preparations – the development of goiter and hypothyroidism. Perchlorate and thiocyanate competitively inhibit the absorption of iodine by the thyroid gland, and TSH stimulates it.

Antithyroid drugs weaken the effect (mutually).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.